Tagrisso Uniunea Europeană - română - EMA (European Medicines Agency)

tagrisso

astrazeneca ab - osimertinib mesilate - carcinom, pulmonar non-celulă mică - alte medicamente antineoplazice, inhibitori de proteinkinază - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

MAGRILAN 20 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

magrilan 20 mg

medochemie ltd. - cipru - fluoxetinum - caps. - 20mg - antidepresive inhibitori selectivi ai recaptarii serotoninei

HUMAGRIP România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

humagrip

lab. urgo - franta - combinatii - compr. + caps. - decongestionante nazale de uz sistemic simpatomimetice

HUMAGRIP România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

humagrip

laboratoires urgo - franta - combinatii - compr. + caps. - decongestionante nazale de uz sistemic simpatomimetice